Novartis blocked from selling Neupogen copycat until Sept 2

NEW YORK (Reuters) - Novartis AG unit Sandoz must wait until Sept. 2 to sell Zarxio, the first biosimilar drug to be approved in the United States and a copycat version of Amgen Inc's $1.2 billion-a-year anti-infection drug Neupogen, a U.S. appeals court said on Tuesday.